About 41% of participants said they would take Mounjaro or another weight management injection if they were allowed to
11 Department of Cell Biology, Physiology and Immunology, Universitat Autnoma de Barcelona (UAB), Bellaterra, Spain
S., & Mulloy, A
The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
For instance, retatrutide trials typically enroll individuals with comorbid conditions such as hypertension or fatty liver and monitor additional endpoints such as knee pain
The list of injectable peptides covers the larger category of compounds that commonly raise this storage question